Sulfuric Acid

Sulfuric Acid

SCHEMBL1940141

CN=C(N)S.CN=C(N)S.O=S(=O)(O)O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 0.47
KDM4E B2RXH2 2/20 0.47
NPSR1 Q6W5P4 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
CA5A P35218 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
TSHR P16473 1/20 0.33
NT5E P21589 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
PMP22 Q01453 1/20 0.31
F2 P00734 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL18584 1.00 BLM (0.47) BLMKDM4ENPSR1CYP2D6CYP2C19
Sulfuric Acid SCHEMBL3892286 1.00 BLM (0.47) BLMKDM4ENPSR1CYP2D6CYP2C19
SCHEMBL1230612 0.83
Sulfuric Acid SCHEMBL5581558 0.80 BLM (0.62) BLMKDM4ENPSR1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL9073672 0.79
Water SCHEMBL11792345 0.79 NOS1 (0.37) NOS1
Sulfuric Acid SCHEMBL10954704 0.71
Sulfuric Acid SCHEMBL27923396 0.69
Sulfuric Acid SCHEMBL526776 0.69
Sulfuric Acid SCHEMBL28217737 0.69 KDM4E (0.53) BLMKDM4ENPSR1CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017384-A1 AZABENZIMIDAZOLE-BASED COMPOUNDS FOR MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION ASTA Medica Aktiengesellschaft (DE) 2000-07-12 EP claimed
WO-1999016438-A1 AZABENZIMIDAZOLE-BASED COMPOUNDS FOR MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1999-04-08 WO claimed
WO-2023138601-A1 BRIDGED RING-SUBSTITUTED HETEROARYL-PYRAN DERIVATIVE, AND USE THEREOF 南京明德新药研发有限公司 2023-07-27 WO disclosed
CN-115298174-A Pyrimido-heterocyclic compounds and application thereof 德昇济医药(无锡)有限公司 2022-11-04 CN disclosed
EP-2897961-A1 DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS Novartis AG (CH) 2015-07-29 EP disclosed
WO-2015089137-A1 ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS KAROS PHARMACEUTICALS, INC. (US) 2015-06-18 WO disclosed
EP-2882746-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Merck Patent GmbH (DE) 2015-06-17 EP disclosed
CN-102083797-B Tetrahydroisoquinolines, pharmaceutical compositions containing them and their use in therapy ABBOTT GMBH & CO KG 2014-06-04 CN disclosed
WO-2014047020-A1 DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2014-03-27 WO disclosed
WO-2014023385-A1 PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-02-13 WO disclosed
CN-103224487-A Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBOTT GMBH & CO KG 2013-07-31 CN disclosed
EP-1144390-A2 KINASE INHIBITORS Amgen Inc., (US) 2001-10-17 EP disclosed
WO-2000043373-A2 KINASE INHIBITORS AMGEN INC. (US) 2000-07-27 WO disclosed
US-5478946-A Treating vascular system disorders or cartilage diseases ABBOTT LABORATORIES (US) 1995-12-26 US disclosed
EP-0296749-A1 (Substituted aralkyl) heterocyclic compounds ZENECA LIMITED (GB) 1988-12-28 EP disclosed
US-4790912-A ELECTROLYTICALLY-GENERATED HYDROGEN AND CATALYST CONVERT METAL SALT IN BATH TO METAL TECHNO-INSTRUMENTS INVESTMENTS LTD. (IL) 1988-12-13 US disclosed
US-4715894-A AMINIMIZATION OF SMEAR TECHNO INSTRUMENTS INVESTMENTS 1983 LTD. (IL) 1987-12-29 US disclosed
US-4657632-A CONTAINING A THIOUREA AND A UREA COMPOUND TECHNO INSTRUMENTS INVESTMENTS 1983 LTD. (IL) 1987-04-14 US disclosed
EP-0216531-A1 Use of immersion tin and tin alloys as a bonding medium for multilayer circuits TECHNO INSTRUMENTS INVESTMENTS 1983 LTD. (IL) 1987-04-01 EP disclosed
US-3944560-A BRONCHODILATOR MERCK & CO., INC. (US) 1976-03-16 US disclosed